NCT07878299 Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity
| NCT ID | NCT07878299 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey |
| Condition | Lipedema |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-09-20 |
| Primary Completion | 2026-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-09-20 with a primary completion date of 2026-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the total and regional body composition characteristics of women with lipedema and women without lipedema who are matched for age and body mass index, as determined by the TANITA MC-580 segmental bioelectrical impedance analysis (BIA) device. In addition to total fat mass and fat percentage, fat mass, fat-free mass, and muscle mass measurements of the right and left legs, right and left arms, and trunk are planned to be evaluated. From these measurements, regional distribution indicators such as the proportion of lower extremity fat mass within total body fat, the leg-to-trunk fat ratio, the leg-to-arm fat ratio, and the leg muscle-to-fat ratio will be calculated. In addition, the study aims to examine the relationships between segmental body composition characteristics and disease type and stage, disease duration, pain severity, and lower extremity function in the lipedema group. Hypothesis: The proportion of total body fat located in the lower extremities is significantly higher in women with lipedema compared to women without lipedema matched for age and body mass index.
Eligibility Criteria
Inclusion Criteria: 1\. Inclusion Criteria (Lipedema Group) 1. Being female. 2. Being between 18-65 years of age. 3. Having received a diagnosis of lipedema based on clinical evaluation. 4. Being willing to participate in the study and signing the written informed consent form. 2\. Inclusion Criteria (BMI-Matched Obese Group) 1. Being female. 2. Being between 18-65 years of age. 3. Not meeting the diagnostic criteria for lipedema on clinical evaluation. 4. Showing similar characteristics to the lipedema group in terms of age and BMI. 5. Being willing to participate in the study and signing the written informed consent form. Exclusion Criteria: 1. Being pregnant or breastfeeding. 2. Having a diagnosis of primary or secondary lymphedema. 3. Having clinically advanced-stage chronic venous insufficiency, an active venous ulcer, or a history of acute deep vein thrombosis. 4. Having a history of surgery or serious trauma within the last 6 months. 5. Having an active infection, cellulitis, or open wound. 6. Presence of edema due to congestive heart failure, advanced renal failure, or decompensated liver disease. 7. Having a diagnosis of active malignancy. 8. Having a neurological, rheumatological, or serious musculoskeletal disease that could affect the assessment. 9. Being unable to comply with study procedures or not providing informed consent.
Contact & Investigator
Feyza Nur Yücel, Assoc. Prof.
PRINCIPAL INVESTIGATOR
Saglik Bilimleri Universitesi
Frequently Asked Questions
Who can join the NCT07878299 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Lipedema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07878299 currently recruiting?
Yes, NCT07878299 is actively recruiting participants. Contact the research team at dr.fny28@gmail.com for enrollment information.
Where is the NCT07878299 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07878299 clinical trial?
NCT07878299 is sponsored by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey. The principal investigator is Feyza Nur Yücel, Assoc. Prof. at Saglik Bilimleri Universitesi. The trial plans to enroll 200 participants.